UNSPSC 51172166: Denaverine hydrochloride

This classification denotes an anticholinergic agent with the molecular formula C24H33NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2AFK8FCD4R, chemically known as benzeneacetic acid, alpha-(2-ethylbutoxy)-alpha-phenyl-, 2-(dimethylamino)ethyl ester, hcl but more generally known as denaverine hydrochloride, which bears US NIH Compound Identifier 18726. European Medicines Agency schedules Denaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01583MIG.

Most nations, for tariff and trade purposes, schedule denaverine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, DENAVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Denaverine hydrochloride bears US NLM NCI C97976. SMILES: CCC(CC)COC(C1CCCCC1)(C2CCCCC2)C(=O)OCCN(C)C.CL.

UNSPSC 51172166 Denaverine hydrochloride is a Commodity code that captures a specific pharmaceutical active ingredient used in criminal justice and public health drug-testing applications. State and local governments soliciting under this code are procuring drug-testing services, pharmaceutical products, and related specimen-collection capabilities that employ denaverine hydrochloride or similar screening compounds as part of offender monitoring, employee health screening, and pharmacy benefit programs. The issuing bodies include county community supervision departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state agencies, local jurisdictions, and healthcare facilities. Work solicited ranges from staffed specimen-collection operations and laboratory screening services with mass-spectrometry confirmation to manufacturer-direct pharmaceutical supply agreements and OTC product distribution through authorized wholesalers.

Recent activity centers in Texas, Minnesota, and participating cooperative-purchasing jurisdictions. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, requesting offender specimen collection and drug testing services with proposals due July 23, 2026, covering approximately 25,031 annual tests across immunoassay screening and confirmatory testing at an estimated contract value of $600,000 over two years with optional renewals. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions, with proposals due March 26, 2026 and contract effectiveness July 1, 2026.